Mounting evidence has shown that the insulin-like growth factor-1 receptor (IGF-1R) has critical roles in cancer cell growth. This has prompted pharmacological companies to develop agents targeting the receptor. Surprisingly, clinical trials using specific IGF-1R antibodies have, however, revealed disappointing results. Further understanding of the role of IGF-1R in cancer cells is therefore necessary for development of efficient therapeutic strategies. Recently, we showed that IGF-1R is sumoylated and translocated into the cell nucleus where it activates gene transcription. Several other studies have confirmed our findings and it has been reported that nuclear IGF-1R (nIGF-1R) has prognostic and predictive impact in cancer. To increase the understanding of IGF-1R in cancer cells, we here present the first study that proposes a pathway by which IGF-1R translocates into the cell nucleus. We could demonstrate that IGF-1R first associates with the dynactin subunit p150 Glued , which transports the receptor to the nuclear pore complex, where it co-localizes with importin-β followed by association with RanBP2. Sumoylation of IGF-1R seems to be required for interaction with RanBP2, which in turn may serve as the SUMO E3 ligase. In the context of sumoylation, we provided evidence that it may favor nIGF-1R accumulation by increasing the stability of the receptor. Taken together, topographic and functional interactions between dynactin, importin-β and RanBP2 are involved in nuclear translocation of IGF-1R. Our results provide new understanding of IGF-1R in cancer, which in turn may contribute to development of new therapeutic strategies.
INTRODUCTION
The insulin-like growth factor-1 receptor (IGF-1R) is a cell surface receptor tyrosine kinase, which is important for growth and survival of cancer cells. [1] [2] [3] Animal studies with antisense strategies have shown that full downregulation of IGF-1R causes complete regression of tumor xenografts. 4 The canonical signaling pathways for IGF-1R-mediated functions depend on the activation of the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/Erk pathways. However, the mechanisms underlying the fundamental roles of IGF-1R in cancer are still not fully understood.
Although the crucial role of the IGF-1R in cancer is unambiguous, several recent clinical phase II and III trials with antibodies specifically directed against the receptor have failed to cause significant antitumor effects. 5, 6 It is hardly possible to obtain a complete downregulation of IGF-1R in clinical settings and if it would be possible it would most likely be risky for the patients. Therefore, it is necessary to identify IGF-1R-mediated actions or mechanisms that are explicitly crucial for cancer cell growth. Discovery and characterization of such mechanisms might lead to development of effective targeted cancer therapies without causing complete downregulation of the receptor.
Recently we demonstrated that IGF-1R undergoes sumoylation, leading to nuclear accumulation of the full-length receptor followed by gene activation by binding to enhancer regions. This constitutes a novel and alternative regulatory mechanism for the receptor. 7 After our discovery of nuclear IGF-1R (nIGF-1R), several other independent studies have supported our findings. [8] [9] [10] [11] [12] [13] [14] It has been shown that increased levels of nIGF-1R correlate inversely with survival in cancer patients. 8, 15 Another study demonstrated high levels of nIGF-1R in malignant cells, but no or low levels in normal cells. 9 These findings suggest a functional impact of nIGF-1R in cancer.
The mechanism behind the nuclear translocation of IGF-1R is largely unknown. Endocytic vesicles can be transported along microtubules (MT) by the MT-dependent motor protein dynein, which guides its cargo towards the MT minus-end, for example, during retrograde axonal transportation and movement of endocytic cargo from the endosome to the lyzosome. 16 Dyneindependent transport typically requires the multisubunit cytosolic protein dynactin, which possesses the activity to drive longdistance vesicle transportation. 17, 18 The largest subunit of the dynactin complex is p150 Glued , which has been shown to interact with MT, and is essential for vesicle transportation. [19] [20] [21] Shuttling of macromolecules between the cytosol and the nucleus is mediated through nuclear pore complexes, which are embedded in the nuclear envelope and create large gateways between the cytosol and the nucleus. Molecule translocation into the cell nucleus is mediated through transport receptors, most of which belong to a large family of related proteins, all of which share homology with importin-β. 22 RanBP2 is a major nucleoporin that extends cytoplasmic filaments from the nuclear pore complex and contains phenylalanine-glycine repeats that bind importinβ. 23, 24 The C-terminal of RanBP2 carries an active SUMO E3 ligase domain. 25 The present study aimed to determine how IGF-1R is transported from the plasma membrane to the cell nucleus and further across the nuclear envelope. We show that nuclear translocation of IGF-1R occurs via a pathway that is facilitated by the dynactin subunit p150 Glued . Moreover, we demonstrate that passage through the nuclear pore complex is mediated by importin-β followed by RanBP2, the latter of which also sumoylates IGF-1R. Disruption of dynactin, importin-β or RanBP2 leads to a significant reduction of nIGF-1R.
RESULTS

nIGF-1R is derived from endocytic vesicles and transported via dynactin interaction
Throughout the study we used the in situ proximity ligase assay (PLA) to investigate protein co-localizations. With this technique, simultaneous primary antibody labeling of two different proteins in close proximity, that is, within 30-40 nm of each other are detected. 26 All PLA results were confirmed with co-immunoprecipitation (IP). We used the non-small cell lung cancer cell line H1299, which strongly expresses nIGF-1R, 10 unless otherwise stated. For comparison, we used the human embryonic kidney cell line HEK293 in all PLA experiments, previously confirmed to express nIGF-1R. 7 Some of the key biochemical experiments were also performed on HEK293 cells. Figure 1 . nIGF-1R is associated with EEA1. (a) Co-localization between nIGF-1R and EEA1 was investigated by PLA (green dots) in H1299 and HEK293 cells. To visualize the cell structure, the slides were co-stained with actin. As a negative control only EEA1 antibody was used and as a positive control two different IGF-1R antibodies were used. (b) Co-localization between nIGF-1R and EEA1 was investigated by IP of nuclei extracts from H1299 cells; nuclear soluble (N s ) and nuclear pellet (N p ). IP with an EEA1 antibody and IgG (negative control) followed by IB for IGF-1R. C-myc and histone 3 were used as markers for the soluble and pellet fractions, respectively. (c) Subcellular localization of endogenous EEA1 in H1299 and HEK293 cells as assayed by IF. Figure 2 . nIGF-1R is dependent on dynactin-mediated transportation. (a) Serum-starved H1299 cells were treated with or without colchicine followed by 50 ng/μl IGF-1 for 60 min and subjected to subcellular fractionation and IB for IGF-1R. Fractions were analyzed with markers of the plasma membrane (Na-K-ATPase) and the nucleus (histone 3). (b) Co-localization between IGF-1R and the dynactin subunit p150 Glued shown by PLA (green dots) in H1299 and HEK293 cells. As a negative control only p150 Glued antibody was used and as a positive control two different IGF-1R antibodies were used. To visualize the cell structure, the slides were co-stained with actin. (c) IP/IB for IGF-1R/ p150 Glued in H1299 cells, IgG/IGF-1R was used as a negative control. (d) Subcellular distribution of IGF-1R after knockdown of p150 Glued or overexpression of dynamitin in H1299 cells. Fractions were analyzed with markers of the plasma membrane (Na-K-ATPase) and the nucleus (histone 3). Total cell lysates (TCL) were analyzed for p150 Glued It has previously been shown that nIGF-1R is dependent on clathrin-mediated endocytosis, but is unaffected by caveolin depletion. 8 As Early Endosome Antigen 1 (EEA1) is important in clathrin-mediated endocytosis and selectively binds internalized vesicles via phosphatidylinositol 3-phosphate, 27, 28 we decided to investigate whether nIGF-1R co-localizes with EEA1. The PLA showed co-localization in both the cytoplasm and the cell nucleus ( Figure 1a ). In this PLA, as well as in all others, we used only one primary antibody (here EEA1) as a negative control and two different antibodies against one of the investigated proteins (here IGF-1R) as a positive control. Actin filaments were stained to visualize the cell structure. To further characterize the colocalization, we performed high salt nuclear extraction resulting in a separation of nuclear material in a soluble and a pellet fraction. IP of EEA1 and detection of IGF-1R in the nuclear soluble (N s ) and nuclear pellet (N p ) fractions showed that the two proteins are present and associated in both fractions ( Figure 1b ). IP of IgG was used as a negative control and detection of EEA1 as a positive control. The fractions were validated by blotting using antibodies against c-myc and histone 3 as markers for the soluble and pellet fractions, respectively ( Figure 1b ). To further confirm that EEA1 is localized in the nucleus as well as in the cytoplasm, we performed immunofluorescence (IF) with an EEA1 antibody in H1299 and HEK293 cells ( Figure 1c ).
MT are the highways for long-distance vesicle transportation in the cell. To assess whether IGF-1R is transported along MT, we first serum-starved cells to diminish the amount of nIGF-1R, followed by treatment with 0.5 μM colchicine for 2 h, a drug well known to cause MT depolymerization. 29 Stimulation of control cells with 50 ng/ml IGF-1 increased nIGF-1R, whereas nIGF-1R in colchicinetreated cells were not affected (Figure 2a ). To further explore our hypothesis, we decided to focus on dynactin, a multisubunit complex that is important for minus-end-directed dyneindependent movement of vesicles along MT. 30 It interacts with EEA1-positive vesicles and its disruption profoundly reduces EEA1 motility. 31, 32 This led us to investigate the role of dynactin in relation to IGF-1R. The largest subunit of dynactin is p150 Glued , which is essential for functional vesicle transportation. PLA revealed co-localization between the IGF-1R and p150 Glued (Figure 2b ). This was supported by IP for IGF-1R and detection of p150 Glued (Figure 2c ). On the basis of these results, we overexpressed the dynamitin subunit of dynactin (fused to mCherry to enable visualization) which causes dynactin complex disruption. 33 We hypothesized that disruption of the dynactin complex would reduce nIGF-1R levels. Accordingly, nIGF-1R was reduced by 50% (P o0.01) after dynamitin overexpression or downregulation of p150 Glued by small interfering RNA (siRNA) compared with mock transfection or control siRNA, respectively (Figures 2d and e ). Expression of downregulated p150 Glued and overexpression of dynamitin are shown in the right panel of Figure 2d . The knockdown efficiency of p150 Glued was quantified to 60% (P o 0.05; Figure 2e , right diagram). The transfection of mCherry-dynamitin was confirmed with IF microscopy ( Supplementary Figure 1 ). Importin-β is mediator of nIGF-1R Several tyrosine kinase receptors, including EGFR and ErbB-2, have been shown to translocate to the nucleus in an importin-βdependent manner. 34, 35 Here, we found that IGF-1R and importinβ were co-localized in the perinuclear and nuclear area in both H1299 and HEK293 cells ( Figure 3a ). This co-localization was confirmed in H1299 cells by IP of importin-β and detection of IGF-1R ( Figure 3b ). To determine if the perinuclear association could be due to the presence of newly synthesized proteins in the ER, based on their perinuclear distribution, cells were treated with cycloheximide (CHX) for 24 h and PLA was performed to detect colocalization of IGF-1R and importin-β. We could not detect any decrease in PLA signals in the CHX treated cells, rather they were increased (Supplementary Figure 2) .
To test if the IGF-1R and importin-β association occurred after dynactin-mediated transportation, we interfered with the dynactin motor activity by overexpressing mCherry-dynamitin as above. We investigated the association between importin-β and IGF-1R by co-IP and found that it was strongly diminished following dynactin complex disruption ( Figure 3c ). Dynamitin overexpression is confirmed in the right panel of Figure 3c . This was confirmed by PLA, showing that dynamitin transfected cells have 83% less IGF-1R-importin-β interactions compared with mock-transfected cells (Po0.001, n = 30; Supplementary Figures 3a and b ).
To investigate whether importin-β could indeed affect nuclear translocation of IGF-1R, importin-β expression was downregulated by siRNA transfection, followed by subcellular fractionation. Quantification of nIGF-1R showed a 46% decrease (Po0.01) after 58% knockdown of importin-β (Po0.05) compared with cells transfected with control siRNA (Figures 3d and e ). Further, we overexpressed the Ran-mutant RanQ69L, thereby disrupting importin-β-mediated nuclear translocation by blocking the GTPhydrolysis, 36 followed by subcellular fractionation and detection of IGF-1R. RanQ69L-transfected cells reduced nIGF-1R by 48% (Po0.05) compared with mock-transfected cells (Figures 3f and g) . Transfection of mCherry-RanQ69L was validated by IF ( Supplementary  Figure 4 ). However, overexpression of RanQ69L did not affect IGF-1R-importin-β association, as assayed by PLA, but it did alter the subcellular localization of the complexes, from normally being perinuclear to spread out in the cytoplasm in RanQ69L-transfected cells ( Supplementary Figures 3a and b ).
We also found that importin-α was co-localized with the IGF-1R ( Supplementary Figures 5a and b ). However, since it has been reported that importin-β can function independently of importin-α, 37 we chose to focus only on importin-β in this study.
RanBP2 is involved in nuclear translocation of IGF-1R
We have previously shown that in the leiomyosarcoma cell line SKUT-1, which is IGF-1R deficient, 38 sumoylation of transfected IGF-1R is a prerequisite for nuclear translocation. 7 In the sumoylation pathway, SUMO is transferred to the substrate with the help of one of several E3 SUMO ligases, which mainly serve to increase the stability of the SUMO conjugation. The nucleoporin RanBP2 represents one of the three known families of SUMO E3 ligases, 25, 39, 40 and it interacts with importin-β. 41, 42 Knowing that IGF-1R sumoylation occurs around the nuclear rim, 7 we hypothesized that RanBP2 may be the E3 ligase for IGF-1R sumoylation. By PLA, we showed that IGF-1R and RanBP2 indeed co-localizes ( Figure 4a ). IP of RanBP2 followed by detection of IGF-1R confirmed the association between the two proteins ( Figure 4b , right panel). Noteworthy, a weaker and a stronger IGF-1R band appeared, around 112 and 125 kDa, respectively. These bands correspond to mono-and di-sumoylated IGF-1R (compared with the left panel of Figure 4b ). Compared with the sumoylated IGF-1R signals after IP/immunoblotting (IB) for RanBP2/IGF-1R the signals are very weak after IP/IB for IGF-1R/IGF-1R (third lane in Figure 4b ). This may have several explanations, for example, difference in IP efficiency or other technical circumstances. Also, probably only a portion of IGF-1R, representing the receptors undergoing passage across the nuclear membrane, 7 is SUMO-modified at a given time point. We can indeed detect stronger bands for SUMO-modified IGF-1R upon IP/IB for IGF-1R/IGF-1R but it requires a prolonged exposure (Supplementary Figure 6) . The 145 kDa IGF-1R band (trisumoylated) could also be detectable under such conditions. In all IP experiments, N-ethylmaleimide, (NEM) was present in the lysis buffer. NEM inhibits SUMO proteases, enabling detection of SUMO-modified proteins. 43 In the absence of NEM, no association between RanBP2 and IGF-1R was observed (Figure 4c ). To evaluate the importance of RanBP2 in nIGF-1R, RanBP2 was downregulated using siRNA. With a strong knockdown efficiency of RanBP2 expression, we observed a 70% decrease in nIGF-1R (P o 0.05; Figures 4d and e ).
To further investigate the E3 ligase activity of RanBP2 on IGF-1R, cells were transfected with an HA-tagged construct encoding the E3 ligase domain of RanBP2 (RanBP2E3, amino acids 2553-2838). This was followed by IP of IGF-1R and detection of SUMO-1 using IB (Figure 5a ). Densitometric analysis showed a 55% increase in sumoylation of the IGF-1R in RanBP2E3-transfected cells compared with mock-transfected controls (P o 0.05; Figure 5b ). However, HA-RanBP2E3 overexpression did not increase the amount of nIGF-1R (not shown). When studying the subcellular distribution of RanBP2E3 by IF compared with endogenous RanBP2, we observed that RanBP2E3 did not localize properly around the nuclear rim (Figure 5c ). We made several trials to overexpress full-length green fluorescent protein (GFP)-RanBP2, but due to low transfection efficiency in H1299 cells (~10%) we did not succeed (data not shown).
Further, we investigated if IGF-1R sumoylation could affect the stability of the receptor. SKUT-1 cells were transfected with either wild-type IGF-1R or with the triple SUMO mutant (TSM) IGF-1R (K1025R, K1100R, K1120R), which is not sumoylated. 7 After 24 h of transfection, the cells were treated with 50 μg/ml CHX for 8 or 24 h (Figure 5d ). All samples were normalized to GAPDH. Samples treated with CHX were compared with the corresponding untreated sample. Quantification showed that TSM was degraded by 59% after 24 h CHX treatment, whereas the wild-type receptor was only degraded by 15% compared with the respective control samples (Figure 5e ). To further assess the stability of IGF-1R, in relation to its sumoylation, we downregulated RanBP2 by siRNA, followed by CHX treatment (Figure 5f ). Quantification showed that when RanBP2 is decreased, the IGF-1R was degraded by 60% compared with 30% degradation in control samples (P o 0.05; Figure 5g ).
RanBP2-IGF-1R association is dependent on dynactin and importin-β
To further investigate the role of RanBP2 and IGF-1R association as a part of the IGF-1R nuclear localization pathway, we disrupted upstream regulators. The dynactin complex was disrupted by dynamitin overexpression (right panel of Figure 6a ) and siRNA was used to downregulate importin-β (middle panel of Figure 6a ). IP experiments on H1299 cells showed that both treatments substantially diminished the IGF-1R-RanBP2 association (left panel of Figure 6a ).
It has been shown that only two point mutations of importin-β (I178A and Y255A, here designated IA/YA mutant) are sufficient to impede the binding between importin-β and RanBP2. 44 We used GFP-tagged importin-β as a template to generate the IA/YA mutant, and we confirmed that it did not bind to RanBP2 (Figure 6b, left panel) . Total cell lysate was analyzed to validate equal transfection efficiency (Figure 6b, right panel) . H1299 cells were transfected with GFP-IA/YA, GFP-importin-β or GFP and subjected to subcellular fractionations (Figure 6c ). Quantification of nIGF-1R showed a 33% reduction in cells overexpressing IA/YA compared with wild-type importin-β (P o 0.01; Figure 6d ). Finally, we used PLA to investigate the association between IGF-1R and RanBP2 after overexpression of either GFP-importin-β or GFP-IA/ YA. Cells overexpressing GFP-IA/YA exhibited a profound reduction of IGF-1R and RanBP2 co-localization (Figure 6e ). We quantified the number of interactions between the two samples and found a significant decrease in GFP-IA/YA-transfected cells (P o 0.01; Figure 6f ).
The pathway for nIGF-1R is IGF-1 dependent
We have previously shown that the nIGF-1R in H1299 cells reaches its maximum 30-60 min after IGF-1 stimulation. 10 In the study by Aleksic et al. 8 it was found that a 15-min stimulation with IGF-1 was sufficient to induce a maximal nIGF-1R expression in DU145 cells, as assayed by IF. To verify the involvement of p150 Glued , importin-β and RanBP2 in this context H1299 cells were serum starved and IGF-1 stimulated in a separate experiment. IP of IGF-1R and IB for either p150 Glued or importin-β showed that their association with IGF-1R peaked at 30 min (Figure 7a) . In contrast, we did not detect any difference in RanBP2-IGF-1R association in serum starved versus IGF-1 stimulated cells (Figure 7b ).
Finally, we investigated whether this pathway is also applicable in other cells than H1299; we disrupted the pathway by overexpressing dynamitin, importin-β mutant IA/YA and RanQ69L in HEK293 cells. All treatments significantly reduced nIGF-1R compared with mock transfection (P o0.05; Figures 7c and d) . Transfection of dynamitin, IA/YA and RanQ69L were confirmed by IF ( Supplementary Figure 7) .
In summary, the present study shows that IGF-1R translocates into the cell nucleus by p150 Glued -dependent transportation, followed by association with importin-β and RanBP2 (Figure 7e ). Abrogation of any of these components leads to a significant reduction in nIGF-1R.
DISCUSSION
During the past few years, nuclear localization of IGF-1R has been proved and nIGF-1R has shown to be implicated in cellular functions. [7] [8] [9] [10] [11] [12] [13] [14] Of special interest, nIGF-1R is overexpressed in cancer cells compared with normal cells 9 and it correlates with poor survival of cancer patients, 8, 15 as well as it affects therapeutic response and resistance. 11, 45 However, this is the first study that presents a pathway by which IGF-1R translocates into the cell nucleus.
We have previously shown that nIGF-1R exists both in the soluble and in the pellet fractions of the nucleus. 7 Here, we investigated nIGF-1R association with EEA1 and found that it occurs both in the soluble and pellet fractions of the nucleus. This result suggests that nIGF-1R binds to membrane structures derived from the endosomal compartment. Consistently, nuclear ErbB-2 has also been shown to be associated with EEA1. 35 Whether there are single endocytic vesicles within the nucleus, as the observed co-localization between IGF-1R and EEA1 in the soluble nuclear fraction might suggest, or if endocytic vesicles have fused to the inner nuclear membrane remains to be explored.
An important finding of this study is that the knockdown of p150 Glued or disruption of the dynactin complex by overexpressing dynamitin resulted in a significant decrease in nIGF-1R, which is also in line with previous reports that p150 Glued disruption affects EEA1 motility. 31, 32 This strongly suggests that the intracellular transport of IGF-1R is dynactin/dynein dependent, which to our knowledge, has not been reported to be involved in nuclear translocation of other tyrosine kinase receptors. Further, we observed that dynactin disruption affected the association of IGF-1R with downstream mediators for nuclear import, that is, both IGF-1R-importin-β and IGF-1R-RanBP2 associations were diminished. Thus, dynactin/p150 Glued mediates the transport of endocytic IGF-1R from the cell membrane to the outer aspect of the cell nucleus, where it supplies importin-β with the receptor.
Both importin-β and RanBP2 are crucial for the import of IGF-1R into the cell nucleus. The interactions with these two molecules occur sequentially; first the receptor binds to importin-β followed by association to RanBP2. A direct interaction between importin-β and RanBP2 is, however, is necessary for an optimal nuclear import of IGF-1R. This was confirmed using an importin-β mutant (I178A/I255A) lacking the RanBP2 binding site. Under this condition, IGF-1R-RanBP2 co-localization as well as nIGF-1R were reduced. As IGF-1R lacks a canonical nuclear localization signal (NLS), it raises the possibility that IGF-1R interacts with a NLScontaining protein to enable binding to importin-β. A well-known IGF-1R interaction partner, insulin-receptor substrate 1 protein, contains a conserved NLS and also translocate into the nucleus. 46 However, we recently showed that nuclear translocation of IGF-1R occurs independently of insulin-receptor substrate 1 protein. 10 Further studies are needed to determine the exact mechanism by which importin-β binds to the IGF-1R.
Immunoprecipitation of RanBP2 followed by IGF-1R detection identified two sumoylated IGF-1R bands. There was no detectable RanBP2 association to the unmodified receptor, suggestion sumoylation of IGF-1R is necessary for a stable binding of RanBP2. However, to detect sumoylated IGF-1R, we always used NEM in the lysis buffer, which inhibits SUMO proteases. It is worth noting that this will affect all SUMO-conjugated proteins in the lysis buffer, thereby potentially affecting other important protein interactions indirectly. The involvement of importin-β-RanBP2 interaction in mediation of nuclear import has previously been described for ErbB-2. 35 However, the critical role of sumoylation, as here shown for the IGF-1R-RanBP2 interaction, in this context is novel.
Interestingly, overexpression of the RanBP2E3 domain increased IGF-1R sumoylation. Although involvement of other E3 ligases cannot be excluded, this finding points to the possibility that RanBP2 itself may act as the SUMO E3 ligase for the receptor and therewith enable IGF-1R-RanBP2 interaction and nuclear translocation. The RanBP2E3 domain could, however, not drive nuclear translocation. This is probably explained by that this construct, in contrast to the endogenous RanBP2, is not localized in the perinuclear regions. This is in agreement with previous observations that the RanBP2E3 domain does not influence nuclear translocation of cargo proteins. 25, 42, 47 We tried overexpressing fulllength GFP-RanBP2, but could not see a difference in nIGF-1R after subcellular fractionation due to very low transfection efficiency, which is most likely caused by the big size of GFP-RanBP2,~400 kDa.
RanBP2E3 has found to be important for the stability of the sumoylated targets. This corroborates with other studies demonstrating that SUMO-1 modification protects targeted proteins from degradation. 48, 49 In order to investigate this matter for IGF-1R, we transfected IGF-1R-deficient human leiomyosarcoma cells (SKUT-1) with either wild-type IGF-1R or a triple SUMO IGF-1R mutant (TSM), which is not sumoylated. 7 We could confirm that the nonsumoylated receptor has a decreased stability compared with the wild-type IGF-1R. This was further supported by the fact that knockdown of RanBP2 decreases IGF-1R stability. Thus, the IGF-1R sumoylation machinery appears to be important for nuclear import for two reasons: firstly, it is necessary for a stable association/interaction with RanBP2 and secondly, it stabilizes the receptor. The sumoylation status may determine how the endocytic IGF-1R-positive vesicles are sorted at the nuclear rim. Adequately sumoylated IGF-1R may be targeted for nuclear translocation, whereas non-sumoylated ones are destined to degradation.
To validate that the proposed pathway is indeed originating from the plasma membrane, cells were serum starved followed by IGF-1 stimulation. As expected, the interaction between IGF-1R and p150 Glued or importin-β peaks at 30 min. However, we could not see a difference in the interaction with RanBP2; serum-starved cells have equally strong IGF-1R interaction as IGF-1-stimulated cells. This further supports our hypothesis that RanBP2 is important for the stability of the receptor. RanBP2-bound IGF-1R might act as a reserve in the cells that protects it from degradation. More studies are needed to clarify the role of RanBP2 in IGF-1R sumoylation and nuclear translocation.
In summary, we propose a pathway for nuclear accumulation of IGF-1R where (I) plasma membrane IGF-1R is internalized by clathrin-mediated endocytosis 8 into EEA1-positive vesicles, which are (II) transported to the nucleus by the microtubule-dependent dynactin/p150 Glued , where (III) importin-β picks up IGF-1R and positions it at the nuclear pore complex to allow (IV) sumoylation by RanBP2 and its final translocation into the nucleus (Figure 7) . Apart from being implicated in cancer phenotypes (see above), nIGF-1R has been shown to interfere with signaling pathways relevant to malignant diseases, for example, it increases transcription by binding to enhancer regions, 7 it interferes with Wnt signaling, 10 it activates nuclear Ca 2+ -signaling 13 and it increases transcription of IGF1R. 12 The molecular characteristics of the pathway of IGF-1 nuclear translocation presented here may be of importance to design new IGF-1R targeted therapies without promoting complete downregulation of the receptor, which seems both risky and unfeasible.
MATERIALS AND METHODS
Antibody against IGF-1Rβ, EEA1, SUMO-1, Na-K-ATPase, c-myc and histone H3 were purchased from Cell Signaling Technology (Danvers, MA, USA). Mouse antibody against IGF-1Rβ and p150 Glued were obtained from BD Biosciences (Stockholm, Sweden). Monoclonal RanBP2 and IgG and GAPDH Carlsbad, CA, USA) and polyethyleneimine, respectively. Transfection with siRNA was carried out with DharmaFECT 2 (Thermo Scientific, Waltham, MA, USA) and the cells were incubated 72 h. SMARTpool siRNA against importinβ and siRNA control were purchased from Dharmacon (Pittsburgh, PA, USA). The siRNA sequences against p150 Glued (5′-GACTTCACCCCTTGATTAA-3′) and RanBP2 (5′-CACTACAATCCCACTGTCC-3′) are described elsewhere. 50, 51 Immnunoblotting and IP
The cells were harvested in modified RIPA lysis buffer (50 mM tris-HCl (pH 7.4), 1% Igepal, 0.25% Sodium deoxycholoate, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 20 mM NEM) and supplemented with complete protease and phosphatase inhibitors. After a 30-min preclearing with 5 μl of Dynabeads protein G (Life Technologies), the lysates were incubated for 1 h with indicated antibody (0.4 to 1 μg) for 1 h at 4°C on an end-over-end rotator followed by overnight incubation with 10 μl Dynabeads at 4°C. The beads were washed three times with lysis buffer and boiled in SDS sample loading buffer for 10 min at 70°C. Subcellular fractions were isolated with Qproteome Cell Compartment Kit (Qiagen, Sollentuna, Sweden) according to the manufacturer's instructions. The high salt nuclear fraction protocol was performed as described previously. 7 Proteins were separated by SDS-PAGE (Life technologies, Stockholm, Sweden) and transferred onto a nitrocellulose membrane (GE Healthcare, Uppsala, Sweden) and detected by IB using primary antibodies overnight at 4°C followed by incubation with horseradish peroxidase-conjugated secondary antibody and visualized with ECL detection reagents (GE Healthcare).
IF
Cells were grown on cover slips and fixed with 4% formaldehyde for 10 min at room temperature, washed three times with phosphate-buffered saline and permeabilized with 0.1% Triton X-100 for 10 min at room temperature. Cells were blocked for 30 min at room temperature in blocking buffer (5% bovine serum albumin blocker (Pierce, Rockford, IL, USA), 5% goat serum (Vector Laboratories, Peterborough, UK) and 0.3% Triton X-100 in phosphate-buffered saline) for 30 min at room temperature. Cells were incubated for 1 h with primary antibody at room temperature in a humidity chamber, followed by incubation of secondary antibodies for 1 h. Slides were mounted on Vectashield with DAPI (Vector Laboratories, Peterborough, UK).
Duolink in situ PLA
The in situ PLA technique kit was purchased from Olink Biosciences, Uppsala Sweden. The PLA was conducted according the manufacturer's recommendation. A wide-field Zeiss (Oberkochen, Germany) Axioplan2 imaging microscope was used for analyzing all IF experiments, at × 40 magnification. Images were acquired with AxioCamHR camera and analyzed in AxioVision 3.1. All images are z-stacked.
Statistical analysis
Immunoblot protein quantifications were carried out by analyzing raw data images from three independent experiments using ImageJ. Protein levels were normalized to a loading control. Two-sided Student's t-test, means and s.d. were calculated.
